GlassScriptPhysician profile
Pavitar S Cheema
NPI 1710996855
$2,005.10
in general payments reported to CMS, 2019-2025
26 companies · $542 in 2025
The $542 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.31 · 2020: $15.78 · 2021: $88.21 · 2022: $242 · 2023: $610 · 2024: $494 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $689.44 | 2023-2025 | Urolift, Barrigel, Solesta |
| Myriad Genetic Laboratories, INC. | $197.60 | 2022-2024 | Prolaris |
| Abbvie INC. | $178.41 | 2022-2025 | Vraylar |
| Olympus America INC. | $147.62 | 2024-2025 | Itind System |
| Sumitomo Pharma America, INC. | $125.40 | 2023-2025 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $80.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $75.12 | 2025 | |
| Boston Scientific Corporation | $55.55 | 2022-2023 | Rezum Generator, Spaceoar Vue System - 10ml |
| Procept Biorobotics Corporation | $55.09 | 2021-2025 | |
| Medtronic, INC. | $48.60 | 2022-2023 | Intellis Adaptivestim |
| Myovant Sciences INC. | $34.72 | 2022 | |
| Astellas Pharma US INC | $33.93 | 2022-2023 | Myrbetriq |
| Laborie Medical Technologies Corp. | $33.89 | 2023 | |
| 180 Medical, INC. | $24.66 | 2023 | |
| Calyxo, INC. | $23.90 | 2025 | Cvac Aspiration System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo USA, INC. | $23.81 | 2024 | Xiaflex |
| Travere Therapeutics, INC. | $23.09 | 2021 | |
| Urogen Pharma, INC. | $20.60 | 2023 | Jelmyto |
| Merck Sharp & Dohme LLC | $19.35 | 2024 | Bridion |
| Ambu INC. | $18.98 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.47 | 2023 | Lynparza |
| Pfizer INC. | $17.16 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.78 | 2020 | |
| Axonics, INC. | $15.19 | 2023 | Bulkamid |
| Mimedx Group, INC. | $14.47 | 2025 | |
| Coloplast Corp | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavitar Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.